Equities Analysts Offer Predictions for Sanofi Q3 Earnings

Sanofi (NASDAQ:SNY) – Equities researchers at Zacks Research raised their Q3 2025 earnings per share (EPS) estimates for Sanofi in a research report issued to clients and investors on Wednesday, January 22nd. Zacks Research analyst K. Shah now anticipates that the company will post earnings of $1.59 per share for the quarter, up from their prior forecast of $1.58. The consensus estimate for Sanofi’s current full-year earnings is $3.82 per share. Zacks Research also issued estimates for Sanofi’s Q1 2026 earnings at $1.06 EPS, Q2 2026 earnings at $1.05 EPS, Q4 2026 earnings at $1.20 EPS and FY2026 earnings at $4.78 EPS.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Friday, October 25th. The company reported $1.57 EPS for the quarter, beating the consensus estimate of $0.22 by $1.35. The company had revenue of $13.44 billion during the quarter, compared to analysts’ expectations of $16.59 billion. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The firm’s revenue was up 12.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.55 EPS.

Separately, StockNews.com downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th.

Sanofi Price Performance

SNY opened at $51.98 on Friday. Sanofi has a 1 year low of $45.22 and a 1 year high of $58.97. The company’s 50 day simple moving average is $48.61 and its 200 day simple moving average is $52.16. The stock has a market capitalization of $131.92 billion, a PE ratio of 26.52, a P/E/G ratio of 1.19 and a beta of 0.57. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00.

Hedge Funds Weigh In On Sanofi

Several hedge funds and other institutional investors have recently modified their holdings of the company. Synergy Asset Management LLC acquired a new stake in Sanofi during the 4th quarter worth approximately $25,000. Northwest Investment Counselors LLC acquired a new stake in shares of Sanofi in the third quarter worth $29,000. Concord Wealth Partners raised its stake in shares of Sanofi by 157.8% in the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company’s stock valued at $34,000 after acquiring an additional 363 shares during the period. Fortitude Family Office LLC lifted its holdings in shares of Sanofi by 708.6% during the 3rd quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock valued at $43,000 after acquiring an additional 659 shares in the last quarter. Finally, Sunbelt Securities Inc. boosted its position in Sanofi by 72.1% during the 3rd quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock worth $43,000 after purchasing an additional 313 shares during the period. 14.04% of the stock is owned by institutional investors and hedge funds.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.